Advertisement
U.S. markets close in 3 hours 21 minutes

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - Nasdaq Real Time Price. Currency in USD
0.2445+0.0215 (+9.64%)
As of 12:31PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2230
Open0.2250
Bid0.2407 x 900
Ask0.2446 x 2200
Day's Range0.2305 - 0.2500
52 Week Range0.1100 - 0.8900
Volume602,910
Avg. Volume989,716
Market Cap53.121M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateMar 13, 2024 - Mar 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.65
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MTNB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Matinas Biopharma Holdings, Inc
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more